Relevance and Clinical Significance of Serum Resistin Level in Obese T2DM Rhesus Monkey Models

Abstract

Resistin is a type of hormone-like adipocytokines, which is secreted specifically by adipocytes. It may be a key factor in the development of type 2 diabetes mellitus (T2DM) from obesity- associated insulin resistance due to results that show that it has a close relationship with insulin resistance in rodents. We utilized the rhesus monkeys as study objects to preliminarily test the association with glucose metabolism and to conduct a correlation analysis for clinical parameters and serum resistin levels in obese rhesus monkey models of T2DM. The results suggested that resistin was significantly increased in T2DM monkeys (P <0.01), and that resistin had a positive correlation respectively with total cholesterol (TC), low-density lipoprotein (LDL-C), fasting plasma glucose (FPG), fasting insulin (FPI) and glycated hemoglobin (HbA1c), Insulin resistance index (HOA-IR), but a negative correlation with islet β-cell function (HOMA-β). In the course of glucose metabolism, reverse release change of resistin and insulin in T2DM monkeys occurred, but the phenomenon that was not observed in the control group, these findings indicated that resistin negatively regulated and interfered with carbohydrate metabolism in T2DM monkey models. The character of the releasing change of resistin might be a unique process in T2DM. Therefore, all of the results could provide references for clinical diagnostic criteria for human cases of T2DM, and could have clinical significance for obese T2DM diagnosis and degree of insulin resistance.

Key words

obese type 2 diabetes mellitus - serum resistin - insulin resistance - clinical significance

• References

• 1 Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
• 2 Steppan CM, Brown EJ, Wright CM et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 16: 502-506
• 3 McTernan CL, McTernan PG, Harte AL et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47
• 4 McTernan PG, McTernan CL, Chetty R et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407
• 5 Mikako DY, Jason EB, Beth EJ et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455
• 6 Lee JH, Chan JL, Yiannakoutis N et al. Circulating resistin levels are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin resistant and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-4856
• 7 Savage DB, Sewter CP, Klenk ES et al. Resistin/Fizz3 expression relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202
• 8 Bobbert P, Eisenreich A, Weithäuser A et al. Leptin and resistin induce increased procoagulability in diabetes mellitus. Cytokine 2011; 56: 332-337
• 9 Helen BH, Hu X, Tyler KX et al. Mechanisms Regulating Adipocyte Expression of Resistin. The Journal of Biological Chemistry 2002; 277: 19754-19761
• 10 Minn AH, Patterson NB, Pack S et al. Resistin is expressed in pancreatic islets. Biochemical and Biophysical Research Communications 2003; 31: 641-645
• 11 Gong HX, Ni YH, Guo XR et al. Resistin promotes 3T3-L1 preadipocyte differentiation. European Journal of Endocrinology 2004; 150: 885-892
• 12 Lu SY, Qi SD, Zhao Y et al. Type 2 diabetes mellitus non-genetic rhesus monkey model induced by high fat and high sucrose diet. Exp Clin Endocrinol Diabetes 2015; 123: 19-26
• 13 Russell WMS, Burch RL. The principles of humane experimental technique. Special edition. (reprint) Mehtuen & Co; London: 1992
• 14 Chen CY, Lee WJ, Asakawa A et al. Insulin secretion and interleukin-1 dependent mechanisms in human diabetes remission after metabolic surgery. Current Medicinal Chemistry 2013; 20: 2374-2388
• 15 Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781
• 16 Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 17 Silva AA, Santos CJ, Amigo H et al. Birth weight, current body mass index, and insulin sensitivity and secretion in young adults in two Latin American populations. Nutr Metab Cardiovasc Dis 2012; 22: 533-539
• 18 Tokuyama Y, Osawa H, Ishizuka T et al. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism 2007; 56: 693-698
• 19 Lim S, Koo BK, Cho SW et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS) A 42-month prospective study. Atherosclerosis 2006; 196: 398-404
• 20 Rajala MW, Obici S, Scherer PE et al. Adipose-derived resistin and gut-derived resistin-like molecule-selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230
• 21 Lee S, Lee HC, Kwon YW et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metabolism 2014; 19: 484-497
• 22 Silha JV, Krsek M, Hana V et al. Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 2003; 58: 736-742
• 23 Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. TRENDS in Endocrinology & Metabolism 2002; 13: 18-23
• 24 Lee WJ, Chen CY, Chong K et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surgery for Obesity and Related Diseases 2011; 7: 683-690